Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.

Autor: Lorusso, Domenica, Mouret-Reynier, Marie-Ange, Harter, Philipp, Cropet, Claire, Caballero, Cristina, Wolfrum-Ristau, Pia, Satoh, Toyomi, Vergote, Ignace, Parma, Gabriella, Nøttrup, Trine J., Lebreton, Coriolan, Fasching, Peter A., Pisano, Carmela, Manso, Luis, Bourgeois, Hugues, Runnebaum, Ingo, Zamagni, Claudio, Hardy-Bessard, Anne-Claire, Schnelzer, Andreas, Fabbro, Michel
Zdroj: International Journal of Gynecological Cancer; Apr2024, Vol. 34 Issue 4, p550-558, 9p
Databáze: Supplemental Index